Recurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Cohort Study in Central China.
anti-N-methyl-D-aspartate receptor encephalitis
anti-NMDA antibody
prognosis
recurrence rate
relapse
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
12
2021
accepted:
01
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
To investigate factors that could impact or predict the probability of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis recurrence in central China. From November 2014 to October 2020, observational data of anti-NMDAR encephalitis inpatients in our institution were collected and analyzed prospectively. The demographics, clinical characteristics, tumor status, lesion locations on MRI and immunotherapies, etc. had entered into a Cox regression model for the identification of the factors associated with relapse-free survival. We enrolled 113 patients in a row (median age: 28 years, range: 1-61 years). The gender distribution was not statistically significant ( Anti-NMDAR encephalitis can recur in around one out of every six cases, and symptoms are generally milder than when it first appears. Recurrence is not related to the severity in the acute phase or the prognosis at follow-up. Patients with ≥3 abnormal sites on MRI or lesions located in the brainstem at onset must be alert to the possibility of recurrence.
Identifiants
pubmed: 35356456
doi: 10.3389/fneur.2022.832634
pmc: PMC8959942
doi:
Types de publication
Journal Article
Langues
eng
Pagination
832634Informations de copyright
Copyright © 2022 Feng, Yang, Cui, Huang, Ji and Lian.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
JAMA Neurol. 2021 Nov 1;78(11):1333-1344
pubmed: 34542573
Neurocrit Care. 2018 Oct;29(2):264-272
pubmed: 29651625
J Pediatr. 2013 Apr;162(4):850-856.e2
pubmed: 23164315
J Clin Epidemiol. 1996 Aug;49(8):907-16
pubmed: 8699212
Expert Rev Neurother. 2015;15(12):1391-419
pubmed: 26559389
J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):757-768
pubmed: 33649022
Eur J Paediatr Neurol. 2015 Jul;19(4):453-63
pubmed: 25792293
Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):265-267
pubmed: 28468084
J Clin Neurol. 2014 Apr;10(2):157-61
pubmed: 24829602
Neurol Sci. 2021 Nov;42(11):4683-4696
pubmed: 33728548
Sci Rep. 2020 Jul 1;10(1):10753
pubmed: 32612192
Diagn Progn Res. 2020 Apr 02;4:3
pubmed: 32266321
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 15;8(2):
pubmed: 33589542
Neurology. 2011 Sep 6;77(10):996-9
pubmed: 21865579
Dev Med Child Neurol. 2019 Sep;61(9):1101-1107
pubmed: 31175679
Neurol Neuroimmunol Neuroinflamm. 2019 Oct 16;7(1):
pubmed: 31619447
J Neuroinflammation. 2016 Nov 1;13(1):281
pubmed: 27802825
J Neuroimmunol. 2017 Nov 15;312:59-65
pubmed: 28935354
J Neurol. 2017 Apr;264(4):647-653
pubmed: 28154970
Neurology. 2008 Feb 12;70(7):504-11
pubmed: 17898324
Eur J Neurol. 2016 Mar;23(3):621-9
pubmed: 26563553
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Ann Neurol. 2007 Jan;61(1):25-36
pubmed: 17262855
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Jan;20(1):48-51
pubmed: 29335082
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
J Neurol. 2015 Aug;262(8):1859-66
pubmed: 25987208